For Q1 FY 2026-27

August 07, 2026 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol: KOPRAN DSuebar: ISnirv/eMstaodra Pmr, esentation on Unaudited Financial Results for the quarter ended June 30, 2026. Dear Sir / Madam, Please find attached Investor Presentation on Unaudited Financial Results for the quarter ended June 30, 2026. The above information will also be made available on the website of the Company www.kopran.com Regards, For Kopran Limited Sunil Sodhani Company Secretary & Compliance Officer Membership No: FCS3897 Encl.: a/a. KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P. B. No. 9917, Tel.: (022) 4366 1111 Fax: (022) 2495 0363 Website: www.kopran.com CIN – L 24230 MH 1958 PLC 011078. E-mail: cs@kopran.com Works:• Village Savroli, Taluka: Khalapur, District: Raigad - 410 202. Tel.: (02192) 274500 / 335 / 337•Fax: (02192) 274025 CORPORATE PRESENTATION Q1 - 2026-27 This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not be deemed to constitute an offer. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be ‘forward-looking statements’, including those relating to the general business plans and strategy of Kopran, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as ‘will’, ‘expected to’, ‘horizons of growth’, ‘strong growth prospects’, among many others, or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, risks with respect to API and Formulation businesses. Kopran may alter, modify, or otherwise change in any manner, the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner. PERFORMANCE • Financial Highlights • Operational Performance • Formulation Q-1 Q-4 Q-1 FY PARTICULARS 2026-27 2025-26 2025-26 2025-26 Revenue from Operations 15,399 23,402 13,522 68,142 EBITDA* 1,588 4,066 1,429 7,825 Finance Costs 328 317 254 1047 Forex Gain/Loss 198 -763 239 -1595 Depreciation 577 452 426 1,747 Tax Expenses 210 648 244 863 Net Profit 670 1,887 745 2,573 EBITDA Margin 10.31% 17.38% 10.57% 11.48% * EBIDTA excluding other income and forex losses OPERATIONAL Kopran PERFORMA NCE APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX FY 2025-26 Q1 - FY 2026-27 (Rs. in Lakhs) (Rs. in Lakhs) 392 146 43 46 129 27 2,551 1,675 Anti- Diabetic 1024 Anti- Diabetic 6,081 4,580 1037 Antibiotic-Urological 142 Anti- Infective Anti-Hypertensive Anti-Hypertensive Anti-Thrombotic 2,315 Carbapenem Anti-Thrombotic 2230 56 Intermediate Carbapenem 394 Anti- Infective Macrolide Intermediate Neuromodulator Macrolide Steriles Cepholosphorin Neuromodulator NSAIDs CNS CNS 18,977 4488 Total Rs. 37,335 Lakhs Total Rs. 9,538 Lakhs APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX FY 2025-26 Q1 - FY 2026-27 (Rs. in Lakhs) (Rs. in Lakhs) 3861 14598 Export Sales Export Sales Local Sales Local Sales 5677 22737 Total Rs. 37,335 Lakhs Total Rs. 9,538 Lakhs Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP FY 2025-26 Q1 - FY 2026-27 (Rs. in Lakhs) (Rs. in Lakhs) 1654 697.92 2559 2084.16 Africa Africa 11733 CANADA Canada Latem Latem Middle East and North Africa Middle East and North Africa South Africa South Africa Southeast Asia UK Southeast Asia 0.60 47.40 12574 492 144 2845.92 33.33 Total Rs. 29,639 Lakhs Total Rs. 5,709 Lakhs Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX FY 2025-26 Q1 - FY 2026-27 (Rs. in Lakhs) (Rs. in Lakhs) 12130 2573 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 17509 3136 Total Rs. 29,639 Lakhs Total Rs. 5,709 Lakhs Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations Technology-focused and approvals by major global regulatory authorities. Company The formulations vertical is operated through Kopran Limited. Serving Regulated and The API vertical is being operated under Kopran Research Laboratories Ltd. Non-Regulated (KRLL), a wholly owned subsidiary of Kopran Limited Markets State-of-the-art Manufacturing Facilities * Our presence across two major verticals in the pharmaceutical value chain API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT ❖ Anti-hypertensive ❖ Development, manufacturing and ❖ Atenolol ❖ Macrolide sale of diverse APIs and Advanced ❖ Neuromodulator Intermediates ❖ Cephalosporins- Non-Sterile& Sterile ❖ Urological ❖ One ofthe leadersin Atenolol ❖ Macrolides ❖ Anti-infective/Anti-acne ❖ Sterile Carbapenem ❖ One of the major players in Sterile ❖ Granules ❖ Sterile Cephalosporin Carbapenems ❖ Anti-thrombotic ❖ SterileCarbapenems ❖ Intermediate ❖ World-class facility and quality ❖ Anti-Diabetic systems ❖ Multipurposeplants ❖ Cardiology ❖ NSAIDs ❖ Cateringexportanddomesticmarket ❖ Pilot plants ❖ Anti Lipid Located at 11,900 sq. mts. 26 FACILITY MIDC Mahad, Products commercialised built-up area Maharashtra FORMULATIONS FORMULATIONS VERTICAL PRODUCT SEGMENTS ❖ Development and manufacturing of oral solid dosages and dry powder PENICILLIN-BASED NON-PENICILLIN formulations for both Penicillin- and Non-Penicillin-based drugs FINISHED ORAL BASED FINISHED ❖ Catering 100% export markets of both Regulated and Non-Regulated DOSAGE FORMS ORAL DOSAGE FORMS markets ❖ Manufacturers of more than 100 dosages meeting the standards of ❖ Anti-infective ❖ Macrolides international markets which includes Tablets, Capsules, Dry Powder and Suspension ❖ Amoxycillin ❖ Anti-hypertensive ❖ Ampicillin ❖ Cardiovascular DEDICATED FACILITIES ❖ Cloxacillin ❖ Anti-helmentics ❖ AmoxyClauv ❖ Anti-histamine ❖ Penicillin-based finished oral dosage forms ❖ EDS ❖ Non-Penicillin-based finished oral dosage forms ❖ Anti-diabetic ❖ CNS Located at ❖ Pain Management 11,432 sq. mts. FACILITY Khopoli, ❖ Gastroenterology built-up area Maharashtra STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP ❖ Focus on R&D to develop niche, ❖ Development of intermediates for APIs high-value/high-volume APIs and intermediates ❖ Reducing dependence on China to move towards self sufficiency ❖ Capacity expansion ❖ Optimising operational cost ❖ Compliance with Global Regulatory standards ❖ Process improvements: Improving yields of existing products ❖ Synergies between APIs and formulations ❖ Atomization of packing lines in formulations ❖ API and R&D facility at Panoli (Gujarat) BUSINESS DEVELOPMENT BALANCE PROFITABILITY & INVESTMENT FOR FUTURE ❖ Leveraging customer base for new products ❖ Prudent capital allocation ❖ New customers and newer geographies ❖ I [Showing first 8,000 characters — download PDF for full document]